[PETDAG] YoY Cumulative Quarter Result on 30-Sep-2012 [#3]

Stock
[PETDAG] PETRONAS DAGANGAN BHD
Announcement Date
29-Nov-2012
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2012
Quarter
30-Sep-2012 [#3]
Profit Trend
QoQ- 58.15%
YoY- 52.58%
Quarter Report
Latest QR
Upcoming QR
PETDAG's Result
PETDAG's Financial Summary
View:
Show?
Cumulative Result
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 31/12/09 31/12/08 CAGR
Revenue 19,123,642 24,888,180 23,955,934 21,826,962 14,844,870 15,269,549 19,992,622 -0.65%
PBT 955,502 697,553 915,657 914,415 591,200 814,905 574,361 7.83%
Tax -253,198 -190,028 -249,246 -248,933 -154,963 -219,846 -164,192 6.62%
NP 702,304 507,525 666,411 665,482 436,237 595,059 410,169 8.29%
-
NP to SH 697,861 501,127 660,433 660,345 432,772 591,827 406,320 8.34%
-
Tax Rate 26.50% 27.24% 27.22% 27.22% 26.21% 26.98% 28.59% -
Total Cost 18,421,338 24,380,655 23,289,523 21,161,480 14,408,633 14,674,490 19,582,453 -0.90%
-
Net Worth 4,997,073 4,857,989 4,818,251 4,808,317 4,665,202 4,398,982 3,993,658 3.37%
Dividend
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 31/12/09 31/12/08 CAGR
Div 397,381 377,512 521,563 521,563 297,778 - - -
Div Payout % 56.94% 75.33% 78.97% 78.98% 68.81% - - -
Equity
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 31/12/09 31/12/08 CAGR
Net Worth 4,997,073 4,857,989 4,818,251 4,808,317 4,665,202 4,398,982 3,993,658 3.37%
NOSH 993,454 993,454 993,454 993,454 992,596 992,998 993,447 0.00%
Ratio Analysis
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 31/12/09 31/12/08 CAGR
NP Margin 3.67% 2.04% 2.78% 3.05% 2.94% 3.90% 2.05% -
ROE 13.97% 10.32% 13.71% 13.73% 9.28% 13.45% 10.17% -
Per Share
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 31/12/09 31/12/08 CAGR
RPS 1,924.97 2,505.22 2,411.38 2,197.08 1,495.56 1,537.72 2,012.45 -0.65%
EPS 70.20 50.40 66.50 66.50 43.60 59.60 40.90 8.33%
DPS 40.00 38.00 52.50 52.50 30.00 0.00 0.00 -
NAPS 5.03 4.89 4.85 4.84 4.70 4.43 4.02 3.37%
Adjusted Per Share Value based on latest NOSH - 993,454
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 31/12/09 31/12/08 CAGR
RPS 1,923.01 2,502.68 2,408.93 2,194.85 1,492.75 1,535.46 2,010.39 -0.65%
EPS 70.17 50.39 66.41 66.40 43.52 59.51 40.86 8.34%
DPS 39.96 37.96 52.45 52.45 29.94 0.00 0.00 -
NAPS 5.0249 4.885 4.8451 4.8351 4.6912 4.4235 4.0159 3.37%
Price Multiplier on Financial Quarter End Date
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 31/12/09 31/12/08 CAGR
Date 30/09/15 30/09/14 30/09/13 28/09/12 30/09/11 31/12/09 31/12/08 -
Price 21.82 20.00 29.00 22.50 15.96 8.70 7.20 -
P/RPS 1.13 0.80 1.20 1.02 1.07 0.57 0.36 18.46%
P/EPS 31.06 39.65 43.62 33.85 36.61 14.60 17.60 8.77%
EY 3.22 2.52 2.29 2.95 2.73 6.85 5.68 -8.06%
DY 1.83 1.90 1.81 2.33 1.88 0.00 0.00 -
P/NAPS 4.34 4.09 5.98 4.65 3.40 1.96 1.79 14.01%
Price Multiplier on Announcement Date
30/09/15 30/09/14 30/09/13 30/09/12 30/09/11 31/12/09 31/12/08 CAGR
Date 02/11/15 04/11/14 31/10/13 29/11/12 23/11/11 19/02/10 24/02/09 -
Price 22.50 20.50 30.60 22.70 16.36 8.58 7.45 -
P/RPS 1.17 0.82 1.27 1.03 1.09 0.56 0.37 18.59%
P/EPS 32.03 40.64 46.03 34.15 37.52 14.40 18.22 8.71%
EY 3.12 2.46 2.17 2.93 2.67 6.95 5.49 -8.03%
DY 1.78 1.85 1.72 2.31 1.83 0.00 0.00 -
P/NAPS 4.47 4.19 6.31 4.69 3.48 1.94 1.85 13.96%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment